solute carrier family 1 member 3Genealiases: EA6 · EAAT1 · GLAST · GLAST1
Q-omics provides the consensus-scored SLC1A3 profile across patient tissues and cancer cell-line models. SLC1A3 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLC1A3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SLC1A3 protein abundance shows 18,808 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where SLC1A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC1A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC1A3 survival associations across molecular data types. SLC1A3 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC1A3 RNA expression–survival associations across cancer types. High SLC1A3 expression shows unfavorable associations in MESO, BLCA and ACC, but favorable associations in SKCM, LUAD and CHOL. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SLC1A3 RNA expression.
This table summarizes SLC1A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC1A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC1A3 shows lower tumor expression in BRCA and higher tumor expression in KIRC, LIHC, KIRP, COAD and THCA. The KIRC box plot shows higher SLC1A3 RNA expression in tumor versus normal tissue (log2 FC = +2.354, t-test p < 0.001).
This table shows molecular features associated with SLC1A3 in patient tissues and cancer cell lines. In patient samples, SLC1A3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC1A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
